InvestorsHub Logo
Followers 280
Posts 33219
Boards Moderated 1
Alias Born 11/14/2013

Re: skitahoe post# 660383

Saturday, 12/30/2023 9:42:34 PM

Saturday, December 30, 2023 9:42:34 PM

Post# of 720678
Gary, I’m not going through the archives tonight, but Google’s Bard did.


DCVax-L and DCVax-Direct in Non-Brain Cancers: Exploring Beyond GBM

While both DCVax-L and DCVax-Direct have primarily been investigated in the context of brain cancers, particularly glioblastoma multiforme (GBM), some limited trials and compassionate use cases offer glimpses into their potential for other cancer types. Here's a breakdown:

DCVax-L:

Phase I Trial for Advanced Ovarian Cancer: Conducted in collaboration with the University of Pennsylvania, this trial assessed the safety and feasibility of DCVax-L in combination with standard treatments. Results haven't been widely published yet.
Compassionate Use Cases: Anecdotal evidence suggests use in various solid tumors including:

Melanoma
Pancreatic cancer
Lung cancer
Breast cancer
Prostate cancer

Limited data makes drawing definitive conclusions about efficacy difficult.

Future Plans: Northwest Biotherapeutics intends to pursue Phase II trials for DCVax-L in other cancer types, depending on resources.

DCVax-Direct:

Phase I/II Trial for Inoperable Solid Tumors: Ongoing at MD Anderson Cancer Center, this trial investigates DCVax-Direct's safety and efficacy in a diverse range of tumors.
Preliminary results showed acceptable safety and potential anti-tumor activity in various cancers, including:

Lung cancer
Pancreatic cancer
Liver cancer
Melanoma
Head and neck cancer
Colorectal cancer
Compassionate Use Cases: Limited reports mention use in non-brain cancers.

Important Points:

Evidence base for both DCVax-L and DCVax-Direct outside of brain cancer is currently limited.

Rigorous clinical trials are needed to conclusively determine their effectiveness in other tumor types.

Anecdotal evidence from compassionate use cases provides preliminary insights but shouldn't be interpreted as definitive proof of efficacy.

Future research holds promise for expanding the potential applications of both DCVax-L and DCVax-Direct beyond brain cancer.
Resources:

Northwest Biotherapeutics website: https://nwbio.com/dcvax-l/
ClinicalTrials.gov: https://clinicaltrials.gov/
The Brain Tumour Charity: https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News